News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

IntegraGen SA Establishes A US Subsidiary To Commercialize Its Molecular Tests In The USA: Robert Gottlieb Appointed CEO Of IntegraGen, Inc.

12/14/2006 9:36:56 AM

Paris, France and New York, USA - 14 December 2006 … IntegraGen SA, the personalized healthcare company focused on the development and commercialization of molecular diagnostic tests for complex diseases, has announced the establishment of IntegraGen, Inc., a wholly-owned US subsidiary, based in New York. Robert Gottlieb has been appointed as its Chief Executive Officer.

Commenting on the move, Mr. Gottlieb said: “It is a pleasure to join IntegraGen as the firm moves toward commercialization of its first product in the United States. The company has done an excellent job discovering and patent protecting biomarkers associated with complex diseases and leveraging the expertise of well respected partners. Based on discussions with researchers and clinicians, IntegraGen is uniquely positioned to deliver molecular diagnostic products that will improve the quality of life for millions of individuals.

In addition to his role as Chief Executive Officer of IntegraGen, Inc, Mr. Gottlieb, who has been working with IntegraGen for the past five months, also holds the position of VP Global Sales and Marketing for the IntegraGen Group, where he has responsibility for sales and marketing of Diagnostic Testing and Counselling services offered through the Company’s Diabetes Competence Center, in Bonn and the Genetic Research Services business, based in France.

Mr. Gottlieb has more than twenty years working experience in the Diagnostics and Medical Device Industry with firms including Abbott Laboratories, General Electric, and Becton Dickinson. Prior to IntegraGen, he was with Roche Diagnostics, where he held a variety of Director level positions. He obtained his M.B.A. from Temple University, Philadelphia, PA, a B.A. in Biology from LaSalle University, Philadelphia, PA.

Dr. Jan Mous, President and CEO of IntegraGen SA, said: “With the incorporation of IntegraGen Inc., the IntegraGen Group has made a significant step forward and allows the Group to effectively market its genetic testing services into this important market.”

“We are very pleased to welcome Rob to the team - his expertise will be critical in helping drive our sales and marketing strategy forward.”

- ENDS -

Notes to editors:

About IntegraGen

IntegraGen is a pioneer in the field of predictive healthcare. The company uses its unique genomic analysis expertise to identify genes associated with complex diseases and commercializes molecular diagnostic tests to enable individualized diagnosis, prevention and treatment.

IntegraGen’s proprietary gene mapping technology GenomeHIP™ provides fast, reliable, and cost-effective discovery of genetic loci. Paired with strong biostatistics, bioinformatics and fine mapping genotyping capabilities, IntegraGen has successfully identified and patented genes associated with early and late onset diseases. Efforts are currently focused on Type-2 Diabetes, Obesity, Autism and Bi-Polar Disorder. Clinical trials for the company’s first genetic test for autism, based on internally identified genes, are planned for Q1 2007.

IntegraGen has two commercial operations. Diagnostic testing and counselling services are offered through a Diabetes Competence Center, based in Bonn, Germany. The Company has recently received accreditation under ISO Standard 17025 for performing human genetic analyses in this Centre. A Genetic Services business, operating out of the company’s headquarters in Evry, France, provides customized genotyping and BAC array services to the research community. The Company also entered recently into a collaborative R&D partnership with the DSM Personalized Nutrition Group.

IntegraGen closed successfully its second financing round raising €8 million ($9.6 million), in 2005. In November 2006, DSM Venturing, the corporate venturing arm of Royal DSM N.V. invested €2M in the Company, bringing the total capital raised by IntegraGen to date to €22 million ($28million). The international syndicate of investors included CDC Entreprises Innovation, AGF Private Equity, Bioam, SGAM Alternative Investments, Baytech Venture Capital, and Avenir Finance Gestion.

Founded in July 2000, IntegraGen has 34 employees and is based in the French Genopole of Evry, near Paris, France, in Bonn, Germany and in New York, USA. More information can be found at

For further information please contact:

Northbank Communications Sue Charles CEO Tel: +44 (0)20 3008 7562

Dr Christelle Kerouedan Account Manager Tel: +44 (0)20 3008 7553 E-mail:

Tony Stephenson Account Manager (Media Relations) Tel: +44 (0)20 3008 8787 E-mail:

At IntegraGen Dr Jan Mous President and CEO Tel: +33 (0)1 60 91 09 00 Email:

Rob Gottlieb CEO, IntegraGen, Inc Vice President, Global Sales and Marketing Tel: +33 (0)1 60 91 09 24 212- 583-4927


Read at

comments powered by Disqus